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OBJECTIVES: Catheter-based renal denervation (RDN) is a new approach to treat
resistant hypertension, a condition that affects approx. 10-15% of hypertensives.
Our objective was to develop a decision-analytic model to assess clinical and cost-
effectiveness of (RDN) from the U.K. National Health Service perspective.
METHODS: A 34-state Markov model predicted cardiovascular endpoints, mortal-
ity, quality-adjusted life years (QALYs), and costs. Input parameters were derived
from multivariate risk equations and other published sources, including the re-
cently published NICE Hypertension Guidance. We evaluated the impact of a 32
mmHg reduction in systolic blood pressure (SBP), from a baseline SBP of 178 mmHg,
in a 42.5% female, 34% diabetic, and 16% smoking cohort with a mean age of 58, as
observed in the Symplicity HTN-2 randomized controlled trial. We calculated ten-
year relative risks and the lifetime incremental cost-effectiveness ratio (ICER) in
£/QALY discounted at 3.5% per year for numerator and denominator. RESULTS:
Relative risks for clinical endpoints were 0.70 for stroke, 0.68 for myocardial infarc-
tion, 0.78 for all coronary heart disease, 0.79 for heart failure, 0.72 for end-stage
renal disease, 0.65 for cardiovascular and 0.82 for all-cause mortality, respectively.
The ICER was £4,870/QALY. CONCLUSIONS: Our model projections suggest RDN
reduces and delays cardiovascular events and is a cost-effective therapy in the U.K.
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OBJECTIVES: Determining cost-effectiveness of ECP in the treatment of patients
with steroid-refractory GvHD after allogeneic HCT, as well as the impact of its
reimbursement on the Polish public payer expenditures. METHODS: The evalua-
tion of the cost-effectiveness of ECP was conducted separately for children/adults
with acute/chronic steroid-refractory GvHD by means of Markov decision model.
Due to the lack of standards of treatment for this group of patients and adequate
clinical studies, analysis was performed without a comparator. Polish cost data
were estimated from the perspective of the public payer (NHF). Discount rates 5%
for costs and 3.5% for health outcomes were used. There was also calculated extra
cost incurred by NHF caused by ECP reimbursement. Two scenarios were consid-
ered: the existing (no ECP reimbursement) and the new (ECP reimbursed) on the
2-year time horizon. For assuming current expenses incurred on GvHD treatment
data published by NHF were used. Savings resulting from the decreased number of
other health services used in GvHD treatment were not considered, so incremental
cost consists merely of the costs of ECP procedure performed. Target population
was estimated at 37-38 patients. RESULTS: The most favorable ratio of health
benefits to costs of therapy in 3-year time horizon was achieved for treatment of
adult patients with acute GvHD – CER ratio 24,103.30 PLN/LY. Others ratios of health
benefits to costs are: 26,772.15 PLN/LY for children with chronic GvHD; 30,473.46
PLN/LY for adults with chronic GvHD and 35,854.39 PLN/LY for children with acute
GvHD. After ECP reimbursement, annual expenses of the public payer on the treat-
ment of acute and chronic GvHD are going to grow by 1,224,736-1,269,300 PLN
(47.92%-49.66%) in the following years of the time horizon. CONCLUSIONS: ECP
seems to be a cost-effective therapy for patients with steroid-refractory, acute and
chronic GvHD with limited impact to Polish public payer budget.
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OBJECTIVES: Heart Failure (HF) admission costs are an important component of
health care resource utilization through the developed world and especially in the
above 65 age group. Cardiac Resynchronization Therapy (CRT) devices have been
proven to reduce HF admissions in indicated patients. Optimal CRT performance
requires periodic device re-programming using simultaneously perfromed cardiac
ultrasounds; however, newer CRT device algorithms continuously and automati-
cally re-program. Ultimately, this continuous optimization maximizes CRT re-
sponse. We approximated health care system cost-savings when aCRT devices are
used over “Traditional” CRT from the perspective of 4 developed geographies.
METHODS: A stratified propensity score analysis estimated Clinical Composite
Score (CCS) differences between technologies. HF admissions/patient-year were
calculated using average rates by CCS. HF admission costs for Payers were obtained
for the UK, Germany, Australia and Canada. Admission rates were extrapolated for
7 years (average CRT-D battery life). RESULTS: Basecase analyses indicate that
aCRT patients could experience an estimated 0.21 less admissions per device im-
planted (17% overall admission reduction) leading to a direct saving per device of
GBP699 (95% CI GBP322-GBP1,001) in the UK; EUR522 (95% CI EUR185-EUR791) in
Germany; AUD1,211 (95% CI AUD427-AUD1,834) in Australia; and CAD1,580 (95% CI
CAD560-CAD2,395) in Canada. Sensitivity analyses which varied the timeframe of
admission rate by CCS and used 0-12 month CCS admission rates estimated a mean
number of avoided HF admissions could reach 0.67 (21.51% overall admission
reduction) which in turn may result in a near tripling of the payer savings men-
tioned above. CONCLUSIONS: aCRT devices appear significantly cost-saving
throughout diverse payment settings; estimates are likely understated since they
include neither follow-up visits (which may be avoided with aCRT) nor avoided
cardiac ultrasounds nor well-documented effects of HF disease progression. CRT
already is proven to reduce mortality and increase QoL at a highly cost-effective
level. aCRT, therefore, certainly has the potential to further improve these out-
comes.
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OBJECTIVES: This prospective study assessed the costs and cost-effectiveness of
routine HIV testing in non traditional settings using Oral fluid-based HIV testing
and a fourth-generation assay. METHODS: HIV tests were offered to patients aged
16-65 over 3 months in 4 settings: Emergency Department, Acute Care Unit, Der-
matology Outpatients and Primary Care in London. We assessed and compared the
costs and the cost-effectiveness ratio of screening in terms of costs for newly
diagnosed HIV-infected patients using the real data derived from each setting.
Additionally, the Survey of Prevalent HIV Infections Diagnosed (SOPHID) was used
to estimate the number of undiagnosed individuals attending each setting over one
year. A sensitivity analysis was run using the SOPHID data to simulate the costs
and cost-effectiveness of the HIV screening in different scenarios, changing the
prevalence and the compliance rates. RESULTS: HIV testing in non traditional
settings cost £19,056.31 per newly diagnosed patient. Using the SOPHID data and
assuming the same compliance rate, the cost for a newly diagnosed patient is
£4,460.59. In the best scenario, assuming 100% compliance, the cost will decrease to
£2,940 per patient. These figures do not take into account the additional cost sav-
ings that may result from earlier diagnosis of HIV-infected individuals.
CONCLUSIONS: The results of the study are really encouraging and suggest that a
screening programme in a high prevalence area could identify HIV-infected pa-
tients at a very low cost. Earlier diagnosis of HIV infection may subsequently have
further cost benefits in terms of aversion of incident infections and early treatment
of infected individuals.
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OBJECTIVES: CRT for Heart Failure (HF) Patients is established as cost-effective.
Nevertheless, optimal functionality requires periodic device re-programming (“op-
timization”) using data from contemporaneous cardiac ultrasounds. Newer CRT
device algorithms continuously re-program, increasing the number of patients
responding to therapy while eliminating the ultrasounds. Maximizing CRT re-
sponse further reduces HF re-admissions. We sought to estimate payer savings
stemming from aCRT device use. METHODS: A stratified propensity score analysis
was performed to estimate response rates, as measured by Clinical Composite
Score (CCS), between aCRT and Traditional CRT. Rates of future HF admissions
were estimated by 6-month CCS using pooled patient-level data from prior CRT
studies. HF admission costs were obtained from the 2009 Medicare Fee Schedule.
Resource utilization and costs were modeled for 7 years following implantation
(average CRT-D Battery Life). RESULTS: Basecase Analyses indicate that aCRT pa-
tients could experience an estimated 0.05 fewer HF hospitalizations in the first 6
months, 0.01 fewer in the next 6 months, and 0.15 fewer in years 2-7 (17% overall
admission reduction). At a cost of $7,977/admission, aCRT is estimated to save
$1,477 per patient; factoring in reductions in cardiac ultrasounds, savings increase
to $1,644 (95% CI $675 – $2,346). Sensitivity Analyses using 0-12 month admission
rates by CCS extrapolated through 7 years estimate that the mean number of
avoided HF admissions could reach 0.67 (21.51% overall admission reduction) –
translating to $5,345 saved. CONCLUSIONS: aCRT Devices appear cost-saving to
payers; Base Case estimates are likely understated since they include neither any
other medical procedures that may be performed in parallel to the cardiac ultra-
sound nor the well-documented effects of HF disease progression. Further research
could better quantify the amount of savings aCRT devices can deliver; since CRT
generally reduces mortality and increases QoL, aCRT may have the potential to
improve the cost-effectiveness of the entire device class.
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